C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) C07H 21/04 (2006.01)
Patent
CA 2601145
Method for predicting the survival of a patient suffering from NSCLC to a cisplatin or carboplatin based chemotherapy treatment which comprises the step of determining the methylation state of a nucleic acid encoding 14-3-3 sigma in a biological sample from the patient, wherein the presence of methylation is indicative of longer survival of said patient as a response to said chemotherapy treatment.The methylation status of the 14-3-3 sigma gene can be easily determined in a serum sample.
L'invention concerne une méthode de prédiction de la survie d'un patient atteint de NSCLC à un traitement chimiothérapeutique à base de cisplatine ou de carboplatine qui comprend l'étape consistant à déterminer l'état de méthylation d'un acide nucléique codant pour un gène 14-3-3 sigma dans un échantillon biologique du patient, la présence de méthylation indiquant une survie plus longue dudit patient en réponse audit traitement chimiothérapeutique. L'état de méthylation du gène 14-3-3 sigma peut être facilement déterminé dans un échantillon sérique.
Costa Rafael Rosell
Taron Roca Miguel
Pangaea Biotech S.a.
Perry + Currier
LandOfFree
Method of predicting the clinical response to platinum based... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of predicting the clinical response to platinum based..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of predicting the clinical response to platinum based... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1409343